Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial

NCT04814030 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: PD-1 inhibitor

Sponsor

Sun Yat-sen University